Stanley Frankel
Direktor/Vorstandsmitglied bei PRECISION BIOSCIENCES, INC.
Vermögen: 54 851 $ am 31.05.2024
Profil
Stanley R.
Frankel is currently an Independent Non-Executive Director at Precision BioSciences, Inc., an Independent Director at Myeloid Therapeutics, Inc., and the Chief Medical Officer at Cytovia Therapeutics, Inc. Previously, he worked as the SVP-Global Drug Development & Cellular Therapy at Bristol Myers Squibb Co. from 2019 to 2020, and as the VP, Head-Clinical R&D, Immuno-Oncology at Celgene Corp.
from 2015 to 2019.
He holds a doctorate degree from Northwestern University and an undergraduate degree from Harvard College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.06.2024 | 4 252 ( 0,06% ) | 54 851 $ | 31.05.2024 |
Aktive Positionen von Stanley Frankel
| Unternehmen | Position | Beginn |
|---|---|---|
| PRECISION BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 12.04.2021 |
Cytovia Therapeutics, Inc.
 Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2021 |
Myeloid Therapeutics, Inc.
 Myeloid Therapeutics, Inc. BiotechnologyHealth Technology Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | 30.06.2022 |
Ehemalige bekannte Positionen von Stanley Frankel
| Unternehmen | Position | Ende |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.10.2020 |
| CELGENE | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2019 |
Ausbildung von Stanley Frankel
| Harvard College | Undergraduate Degree |
| Northwestern University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PRECISION BIOSCIENCES, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cytovia Therapeutics, Inc.
Cytovia Therapeutics, Inc. BiotechnologyHealth Technology Cytovia Therapeutics, Inc. engages in transformational immunotherapies for cancer and severe acute infectious diseases. Its products include Multi-Specific NK Engager Antibodies and iPSC CAR NK cells. The company was founded by Daniel Teper, Gilles Seydoux, and Massimo Radaelli and is headquartered in New York, NY. | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Myeloid Therapeutics, Inc.
Myeloid Therapeutics, Inc. BiotechnologyHealth Technology Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA. | Health Technology |
